Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0041-1345(98)01393-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Interaction of the chlorite-based drug WF10 and chlorite with hemoglobin, methemoglobin and ferryl hemoglobin.
Arch Biochem Biophys
November 2015
Institute for Medical Physics and Biophysics, Medical Faculty, University of Leipzig, Härtelstraße 16 -18, 04107 Leipzig, Germany. Electronic address:
The interaction of the chlorite-based drug solution WF10 with human oxyhemoglobin and oxidized hemoglobin forms was investigated monitoring the corresponding spectral changes in heme states. The chlorite component of WF10 converts oxyhemoglobin into methemoglobin with a rate of 35.4 M(-1)s(-1).
View Article and Find Full Text PDFHemorrhagic radiation cystitis.
Am J Clin Oncol
June 2015
*Department of Radiation, University of Florida Proton Therapy Institute †Division of Urology, College of Medicine, University of Florida, Jacksonville, FL.
The optimal management of persistent hemorrhagic radiation cystitis is ill-defined. Various options are available and include oral agents (ie, sodium pentosan polysulfate), intravenous drugs (ie, WF10), topical agents (ie, formalin), hyperbaric oxygen, and endoscopic procedures (ie, electrical cautery, argon plasma coagulation, laser coagulation). In general, it is best to manage patients conservatively and intervene only when necessary with the option least likely to exacerbate the cystitis.
View Article and Find Full Text PDFClinical outcomes of WF10 adjunct to standard treatment of diabetic foot ulcers.
J Wound Care
March 2013
Department of Surgery, Srinakharinwirot University, Nakom Nayok, Thailand.
Objective: To study clinical outcomes and safety of WF I 0 as an adjunct to standard treatment for diabetic foot ulcers (DFU) and to determine the optimal number of WF I 0 cycles that should be administered.
Method: A prospective, open-label study of WF I 0 adjunct to standard treatment for severe DFU but salvageable foot was carried out between July 2009 and June 20 I 0. Patients were classified into three groups, according to common clinical presentations: neuropathic ulcer, ischaemic ulcer and severely infected ulcer.
Effect of WF10 (immunokine) on diabetic foot ulcer therapy: a double-blind, randomized, placebo-controlled trial.
J Foot Ankle Surg
March 2012
Department of Surgery, Faculty of Medicine, Srinakharinwirot University, Nakorn Nayok, Thailand.
This randomized controlled trial was undertaken to evaluate the effect of WF10 (Immunokine) as an adjunct to the standard treatment of diabetic foot ulcer. A total of 40 participants were randomized into 2 groups of 20. One group underwent standard therapy combined with infusions of WF10, and 1 underwent standard therapy combined with placebo.
View Article and Find Full Text PDFWF10 stimulates NK cell cytotoxicity by increasing LFA-1-mediated adhesion to tumor cells.
J Biomed Biotechnol
November 2011
Institute for Immunology, University Heidelberg, Im Neuenheimer Feld 305, 69120 Heidelberg, Germany.
The redox-active chlorite-based drug WF10 (Immunokine) was shown to have modulatory effects on both the innate and adaptive immune system in vitro and in vivo. Animal studies suggest that WF10 enhances immunity against tumors. One possible explanation for such an effect is that WF10 stimulates natural killer cell cytotoxicity against malignant cells.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!